YN001 + evolocumab

This is a **combination therapy** of YN001 and evolocumab, investigated for treating coronary atherosclerosis. **YN001** is an intravenously administered agent under clinical investigation for coronary atherosclerosis, but its precise molecular identity and mechanism have not been established in public sources. **Evolocumab** is a fully human IgG2 monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), increasing the number of LDL-receptors on hepatocytes and thus lowering LDL cholesterol. **Evolocumab** is FDA and EMA approved for lowering LDL-C in hypercholesterolemia and reducing cardiovascular risk in established atherosclerotic cardiovascular disease. The combination is being evaluated for additive or synergistic lipid-lowering and vascular protective effects.